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Background: Extracellular vesicles (EVs) are secreted from many cells, carrying cargoes including proteins and
nucleic acids. Research has shown that EVs play a role in a variety of biological processes including immunity, bone
formation and recently they have been implicated in promotion of a metastatic phenotype.
Methods: EVs were isolated from HCT116 colon cancer cells, 1459 non-malignant colon fibroblast cells, and tumor
and normal colon tissue from a patient sample. Co-cultures were performed with 1459 cells and malignant vesicles,
as well as HCT116 cells and non-malignant vesicles. Malignant phenotype was measured using soft agar colony
formation assay. Co-cultures were also analyzed for protein levels using mass spectrometry. The importance of
14-3-3 zeta/delta in transfer of malignant phenotype was explored using siRNA. Additionally, luciferase reporter
assay was used to measure the transcriptional activity of NF-κB.
Results: This study demonstrates the ability of EVs derived from malignant colon cancer cell line and malignant patient
tissue to induce the malignant phenotype in non-malignant colon cells. Similarly, EVs derived from non-malignant colon
cell lines and normal patient tissue reversed the malignant phenotype of HCT116 cells. Cells expressing an EV-induced
malignant phenotype showed increased transcriptional activity of NF-κB which was inhibited by the NF–κB inhibitor,
BAY117082. We also demonstrate that knock down of 14-3-3 zeta/delta reduced anchorage-independent growth of
HCT116 cells and 1459 cells co-cultured with HCT derived EVs.
Conclusions: Evidence of EV-mediated induction of malignant phenotype, and reversal of malignant phenotype,
provides rational basis for further study of the role of EVs in tumorigenesis. Identification of 14-3-3 zeta/delta as
up-regulated in malignancy suggests its potential as a putative drug target for the treatment of colorectal cancer.
Keywords: Extracellular vesicles, Liquid chromatography-tandem mass spectrometry, Colorectal cancer, Proteomics,
14-3-3, STAT1, IQGAP1, Raf-1, prohibitin, NF-κB, Luciferase reporter assayBackground
Colorectal (CRC) cancer is the 2nd most prevalent can-
cer in women and the 3rd most prevalent cancer among
men, globally [1]. Incidence of colorectal cancer is high,
with an estimated 1.35 million new cases reported in
2012 [1]. It is estimated that nearly 700,000 patients died
of colorectal cancer in 2012 [1]. Recent declines in mor-
tality can be attributed to improved screening processes* Correspondence: Devasis_chatterjee@brown.edu
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creativecommons.org/publicdomain/zero/1.0/and treatment plans including surgical resection of tumor
tissue, adjuvant chemotherapy and radiation. Postopera-
tive drug therapy is key in targeting micro-metastasis that
may be missed during surgery [2]. However, even with
medical advances, the average 5-year survival rate of pa-
tients is a moderate 64.9 % [3]. This statistic fails to
emphasize the impact of disease presentation at diagnosis
on the outcome. Early diagnosis of localized disease (stage
II) yields a 90.3 % survival rate, but this decreases signifi-
cantly to a modest 70.4 % survival rate in patients diag-
nosed with regional disease (stage III). The 20 % of
colorectal cancer cases that are diagnosed in late stage,rticle distributed under the terms of the Creative Commons Attribution License
which permits unrestricted use, distribution, and reproduction in any medium,
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[3]. Recent research focuses on the genetic and epigenetic
differences in the tumors of colorectal patients to help de-
velop more targeted therapies, tailored to each patient to
maximize efficacy. For example, anti-EGFR treatments, in-
cluding panitumumab and cetuximab, have been shown
to improve outcome for patients with tumors carrying
wild-type KRAS gene. Conversely, mutations in KRAS, as
well as PTEN, BRAF and PIK3CA have been implicated as
causative in patients resistant to anti-EGFR treatments
[4]. Thus, there is a need for a more expansive body of tar-
geted therapies for improved clinical outcome. Consider-
able research has focused on understanding the tumor
microenvironment, specifically, soluble factors secreted
and taken up by cells [5–7]. A variety of cell types release
microvesicles (MVs), or exosomes, collectively termed
extracellular vesicles. Ranging in size from 30-1000 nm,
these vesicles are released into the surrounding environ-
ment through fusion of a multivesicular endosome with
the plasma membrane or through direct blebbing off the
plasma membrane [8]. Once regarded as cellular debris
and first studied as mediators of immune action, vesicle
contents have been identified to include various types of
proteins, nucleic acids and other bioactive molecules. The
role of EVs is especially important in regards to tumor
progression, because cancer cells have been shown to se-
crete EVs at an elevated rate. More importantly, higher
levels of EVs have been shown to correlate with advanced
stages of cancer [9, 10]. Further understanding of the
mechanisms underlying increased EV secretion in cancer,
and the mechanisms behind phenotypic transfer, are cru-
cial to the potential identification of many novel thera-
peutic targets.
Recent evidence suggests a role of horizontal transfer
of information via EVs in tumorigenesis, including the
transfer of specific aspects of cellular phenotype and ac-
tivation of specific signaling pathways [11]. One study
analyzing colorectal cancer EV contents found mutant
KRAS protein was present in EVs isolated from DKO-1
cells with KRAS mutation. They were further able to
show transfer of the mutant KRAS protein to DKO-8
cells inherently expressing only wild type KRAS, after
co-culture with DKO-1 extracellular vesicles [12]. An-
other study compared protein contents in vesicles iso-
lated from primary CRC cells (SW480) and metastatic
CRC cells (SW620). Findings showed differential protein
expression, with primary cancer vesicles dense in cell-
adhesion proteins and metastatic cancer cells dense in
proteins important for regulation of cell cycle [13].
In this study, we demonstrate that EVs play an import-
ant role in tumor microenvironment through the pro-
motion of malignant phenotype. We show an induction
of malignant phenotype, as measured by growth in soft
agar. Anchorage independent growth, a characteristic ofmalignancy, was induced in non-malignant colon fibro-
blast cells (1459) after co-culture with EVs isolated from
malignant colon cells (HCT116). The reciprocal result
occurred with HCT116 cells co-cultured with 1459
vesicles showing a reduction in anchorage independent
growth. Vesicles harvested from normal (Colo and
004CT Normal) and malignant (004CT Tumor) patient
colon tissue were shown to induce the same changes in
phenotype as vesicles isolated from immortalized cell
lines, providing rational basis for further exploration into
the role of EVs in promotion of metastatic disease. We
found an increased expression of the proteins 14-3-3
zeta/delta, prohibitin, phosphorylated Raf kinase Inhibi-
tor Protein (pRKIP) and Signal Transducer and Activa-
tor of Transcription1 (STAT1) in 1459 cells acquiring
malignant phenotype after co-culture with malignant
EVs. Additionally, an increase in transcription of NF-κB
was observed after co-culture with malignant EVs. Our
study also shows that 14-3-3 zeta/delta is important in
the EV mediated induction of malignant phenotype, sug-




All chemicals and reagents were purchased from Sigma
Chemical Co. (St. Louis, MO) unless otherwise noted. Pro-
tein quantification reagents were obtained from Bio-Rad
Laboratories, Inc. (Hercules, CA). Enhanced chemilu-
minescence reagents as well as secondary mouse and
rabbit horseradish peroxidase-conjugated antibodies for
Western blot analysis were from GE Healthcare
(Arlington Heights, IL). The primary antibodies to Raf-
1 (sc-133), actin (sc-1616), prohibitin (sc-6705), STAT1
(sc-346), pRKIP (sc-32623) and 14-3-3 zeta (sc-1019)
and 14-3-3 zeta siRNA (sc-29583) were all purchased
from Santa Cruz Biotechnology (Santa Cruz, CA). The
antibody to RKIP (07-137) was purchased from Millipore
(Billerica, MA).
Cells
Human colon tumor cells were grown in RPMI with 10 %
fetal bovine serum, 100 IU/mL penicillin, 100 μg/mL
streptomycin, 1 μg/mL metronidazole, 2.5 μg/mL ampho-
tericin and 20 μg/mL gentamicin. The human adenocar-
cinoma cell line, HCT116 and human normal colon
fibroblast cell line 1459 were purchased form ATCC
(Rockville, MD). HCT116 cells were cultured in McCoy’s
5A and 1459 cells in Eagle’s Minimum Essential Medium
(EMEM). Both mediums were supplemented with 10 %
fetal bovine serum (FBS), 1 % glutamine, 1 % non-
essential amino acids, 100 IU/mL penicillin and 50 IU/mL
streptomycin. All cells were cultured in a humidified incu-
bator containing 5 % CO2 at 37 °C.
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Total cell extracts were prepared as previously stated [14].
The protein concentrations of lysates were determined
using either BCA protein assay kit (Pierce) or Bradford
assay kit (BioRad). Proteins were separated using 10 %
SDS-PAGE and electrophoretically transferred from the
gel to nitrocellulose membranes (GE Healthcare). En-
hanced chemiluminescence reagents (GE Healthcare)
were used to detect proteins recognized by the antibodies.
Tissue collection
Human colon tissue samples were obtained on October 23,
2012 and January 11, 2013. Consent for the collection of
patient human colon cancer samples was written and
informed and obtained according to the Rhode Island
Hospital’s Committee on Protection of Human Subjects
(Institutional Review Board). The tumor samples were col-
lected and transported in Roswell Park Memorial Institute
medium (RPMI) supplemented with 500 IU/mL penicillin,
500 mg/mL streptomycin, 100 μg/mL gentamicin, 12.5 μg/
mL amphotericin and 5 μg/mL metronidazole.
Extracellular vesicle isolation
Extracellular vesicles were isolated from two different
patient tissue samples under approval of the Institutional
Review Board at Rhode Island Hospital. Tissue samples
were weighed and minced with a sterile scalpel into 1-
2 cm pieces as previously reported [15]. Enzymatic dis-
sociation was performed on each of the tissue pieces
using 0.2 % collagenase in RPMI with 10 % FBS for
90 min at 37 °C. The tissue pieces were passed sequen-
tially through 18, 22 and 25 gauge needles followed by a
40 um cell strainer, as reported [15]. Resulting cell sus-
pensions were washed twice with RPMI and grown in a
T-75 tissue culture flask. Cells were grown in RPMI
media supplemented with 10 % EV-free FBS, 1 % glu-
tamine, 1 % nonessential amino acids, 100 IU/mL peni-
cillin and 50 IU/mL streptomycin. HCT116 cells and
1459 cells were plated at 1.5x105cells per T-75 flask
prior to vesicle isolation.
Conditioned medium was collected 7 days after cul-
ture and processed to isolate the extracellular vesicles.
The medium was centrifuged at 300 x gravity for 10 min
at 4 °C. The UCF (ultra centrifuged) supernatant was
isolated after centrifugation at 28,000 x gravity for 1 h at
4 °C. The UCF pellet was suspended in growth medium
and co-cultured with cells for 7 days (see below).
Protein lysate preparation from EVs
EVs were harvested from HCT116 cells and underwent
differential centrifugation: 300 x g for 10 min, 2000 x g
for 30 min, 10,000 x g for 30 min (microvesicle pellet)
and then 100,000 x g for 60 min (exosome pellet). To
isolate the total EV fraction, the 10,000 x g was skippedafter the 2000 x g spin. The different fractions were
lysed in RIPA lysis buffer for 30 min on ice. The super-
natant was collected for Western blot analysis following
centrifugation at 13,000 rpm for 10 min. For Western
blot analysis, 10 μg protein samples were separated on
10 % SDS-PAGE and transferred to a nitrocellulose
membrane.
Co-culture of colon derived extracellular vesicles with
non- and malignant colon epithelial cell lines
Malignant HCT116 cells were grown in McCoy’s medium
and non-malignant 1459 colon cells were grown in
EMEM medium seeded at a density of 1x105 cells per
plate. The number of EVs used for co-culture was normal-
ized by using the NanoSight NS500 (NanoSight, Wiltshire
United Kingdom) to count the total number of EVs within
particular size 30-1000 nm. Each dish received 2 X 108
EVs. 1459 cells were co-cultured with EVs from HCT116
cells and HCT cells were co-cultured with EVs from 1459
cells. Additionally, HCT116 cells and 1459 cells were co-
cultured with EVs from both normal and malignant colon
tissue. Cell lines were also co-cultured with their own iso-
lated EVs for comparison. Co-cultures were maintained
for 7 days in 5 % CO2 at 37 °C.
Soft agar assay
Cells were harvested for soft agar cloning after a 7 days
co-culture with EVs. Soft agar cloning was examined
using 0.7 % agarose in PBS and mixed with 1× media
with 15 % FBS. The top layer consisted of 0.35 % agarose
in PBS, 1× media with 22.5 % FBS and 1 x 105 cells per
dish. Observations were made under the 40x objective
and images of the plates were captured by a Nikon
TE200 microscope.
Gray-scale Images (8 bit) were acquired with a Nikon
TE200 inverted microscope (Nikon Inc. Melville NY)
using a 10X Plan Fluor objective. Images were captured
with a Spot RT3 digital camera (Diagnostic instruments,
Sterling Heights MI) using the cameras built-in green fil-
ter to increase image contrast. iVision image analysis
software (BioVision Technologies version 4.5.4, Exton,
PA) was used to calculate area of the colonies. Images
were calibrated so area measurements are expressed in
micrometers.
Migration assay
To assess migration, HCT116 control,1459 control, and
HCT116 treated with 1459 EV (7 days) cells were plated
in serum free medium in the upper chamber of a of an
8 μm pore Transwell filter (BD Bioscience, Bedford,
MA) coated with Matrigel in a 24-well dish. Assays were
set-up with 250,000 cells per condition. Cells were
allowed to migrate at 37 °C, 5 % CO2 for 48 h, fixed
with methanol and stained with 0.1 % w/v crystal violet.
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ing cells were determined in each well. Experiments
were performed in triplicate and repeated twice.
Protein extraction
Protein lysates from co-culture experiments and control
cells were obtained after 7-day incubation using a Ready-
Prep Sequential Extraction Kit (Bio-Rad). A ReadyPrep
2-D Clean-Up Kit (BioRad) was then used to combine
and clean the sequential extractions. Total protein con-
centration was found using a BCA protein assay kit
(Thermo Scientific). NuPAGE SDS-PAGE system (Invi-
trogen) (4-12 % acrylamide, Bis-Tris with MES SDS
Running Buffer) was used to resolve the samples, and
they were stained with Gel Code Blue Stain (Thermo
Scientific). In order to reduce sample complexity, gel
lanes corresponding to each sample were excised into 3
bands: high, medium and low molecular weight proteins.
Each band was cut into 6 mm wide pieces before subjec-
tion to in-gel tryptic digestion. Post-digestion, the frac-
tions were washed/dehydrated twice in a 1:1 solution of
1.0 M ammonium bicarbonate (Sigma) and 100 % ACN
(Sigma). Disulfide bonds were reduced with 10 mM di-
thiothreitol (DTT) (Thermo)/0.1 ammonium bicarbon-
ate for 45 min at 56 °C and alkylated with 55 mM
iodoacetamide (IAA) (Sigma) for 30 min at room
temperature, in the dark. Samples were washed/dehy-
drated twice, as explained above, and then digested by
overnight with trypsin at 37 °C. Peptides were extracted,
after trypsin digestion, using 25 mM ammonium bicar-
bonate and 100 % ACN, followed by two rounds of 5 %
formic acid and 100 % ACN. Extracts were combined,
dried using a vacuum centrifuge, and stored at -20 °C
until LC/MS analysis.
Liquid chromatography/ MS analysis of protein digests
Rhode Island Hospital COBRE Proteomics Core facility
performed all mass spectrometry analysis by nano-LC-
ESI-MS/MS using an Ultimate3000 nano-LC system
(Dionex) controlled with Chromeleon software coupled
to a QSTAR XL (Applied Biosystems, Concord, Ontario,
CA) mass spectrometer. Tryptic digests were fraction-
ated by reverse-phase chromatography using a C-18
PepMap 100 column (75 um id x 15 mm, 3um particle
size, LC Packings/Dionex, Sunnyvale, CA) operating at a
flow of 300 nL/min. Over a 40 min time period, a linear
separation gradient was applied starting at 5 % (v/v)
CAN in 0.1 % (v/v) formic acid (Buffer A) to 95 % (v/v)
ACN in 0.1 % (v/v) formic acid (Buffer B). ESI was used
to introduce the column elutate directly into the mass
spectrometer.
Candidate ions were selected and fragmented using a
standard information dependent acquisition (IDA)
method. During MS/MS scans, one-second MS scans(range between 350 and 1800 Thompson, Thompson
(Th) = Da/z) were used to identify candidates for frag-
mentation. MS/MS scans (2 s; range between 150 and
1800 Th) were collected up to three times after each sur-
vey scan. Candidates considered for fragmentation re-
quired an assigned charge in the range of +2 or +4.
Data processing for protein identification and
quantitation
Raw LC-MS/MS data was converted to mgf format using
ABSciex MS Data converter software (v1.3 beta). Data in
mgf format was used for protein identification with MAS-
COT v2.3.2 search engine (Matrix Science, Boston, MA,
USA) by searching against a non-redundant human
UniProt database (April 20th, 2012, containing 87, 656
protein entries). Parameters included the following: tryptic
peptides with up to two missed cleavage sites, peptide tol-
erance of 0.2 Da, fragment tolerance of 0.5 Da, instrument
type: ESI-QUAD-TOF, and variable modifications: me-
thionine oxidation.
Raw files were converted to mzXML format using
ABSciex MS data converter software (v1.3 beta) and
uploaded along with MASCOT search results in .dat for-
mat into ProteoIQ software (v.2.3.08 BIOINQUIRE,
Athens, GA, USA), for label-free protein quantitation
and proteome comparisons. Spectral counting and rela-
tive intensity quantification were performed using pre-
cursor ion intensities. Parameters included the following:
mass tolerance of 20 ppm, minimum peptide length of 6
amino acids, protein probability of 0.5, and peptide
probability of 0.05. Proteins were further filtered using
0.9 protein probability and normalized according to the
number of spectra in each sample.
NF-κB luciferase reporter assay
Lipofectamine in serum-free medium was used to transi-
ently transfect cells (3 x 105 cells/60 mm dish) with
0.25 μg of a reporter plasmid containing NF-κB binding
fragments with controls, as we have previously reported
[16]. OptiMEM containing FBS was added to the cells
after 3 h, at a final concentration of 20 %. Cells were
harvested by scraping, washed twice with PBS and lysed
in passive lysis buffer (Promega). Dual-Luciferase Re-
porter Assay (Promega) was used to evaluate the lucifer-
ase activity in the cytosolic supernatant in the presence
of absence of the NF-κB inhibitor, BAY11-7082 (BAY). A
luminometer (Lumat LB 9507, Berthold Technologies)
was used to estimate transcriptional activity.
Application of Small Interfering RNA (siRNA) against 14-3-3
HCT116 cells were plated in a 6-well plate, 24 h prior to
transfection, in an antibiotic free growth medium. siRNA
against 14-3-3 zeta, or equivalent amount of control
siRNA solution, was mixed with a transfection reagent
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for 30 min at room temperature. Cells were washed with
OptiMEM and incubated for 6 h with the siRNA mix
and OptiMEM. After 6 h, 1 ml of medium supplemented
with 20 % FBS was added to the cells. Incubation was
continued for a total of 48 h before harvesting. Western
blot analysis was used to confirm inhibition of 14-3-3
zeta protein expression.
Statistical methods
Cell culture experiments were all repeated a minimum
of 3 times, unless otherwise indicated. Paired t-tests
were used to determine statistical significance. P-values
of 0.05, or less, were considered statistically significant.
Results
Extracellular vesicle-mediated induction of malignant
colon cancer phenotype
Anchorage independent growth is a major hallmark of
malignant cells; therefore, we quantified EV-mediated
phenotype changes in malignant colon cells using soft
agar colony formation. EVs were harvested from a malig-
nant human colon tumor cell line (HCT116) and from a
patient tissue sample of malignant colon tumor (004CT
Tumor). Two co-cultures were prepared with normal
human colon fibroblast cell line 1459: 1459 + HCT116
EVs and 1459 + 004CT Tumor EVs. After a 7-day period
of culture, each experimental condition was grown in
soft agar to measure ability of anchorage independent
growth. Malignancy includes increased anchorage-
independent growth, so an increase in the number of
colonies was viewed as a shift towards malignant pheno-
type. 1459 cells co-cultured with HCT116 EVs displayed
a significant increase (p < 0.00001) in colony formation
in comparison to the 1459 control cells (Fig. 1). The co-
culture of 1459 and patient derived 004CT Tumor EVs
also displayed a significant increase (p < 0.000001) in col-
ony formation, suggesting an induction of malignant
phenotype by EVs isolated from malignant colon tumor
cells (Fig. 1). EVs from HCT116 cells were also co-
cultured with HCT116 cells to determine if vesicles
impact their own cells. There was no significant
change in the number of colonies formed by the
HCT116 + HCT116 EV co-culture, compared to HCT
control (p = 0.33).
Extracellular vesicle-mediated reversal of malignant colon
cancer phenotype
EVs were harvested from a normal human colon fibro-
blast cell line (1459), as well as two patient tissue
samples of normal colon epithelium (004CT Normal &
Colo). Three different co-cultures were set up with ma-
lignant human colon tumor cell line HCT116, as follows:
HCT116 + 1459 EV, HCT116+ 004CT Normal EV,HCT116 + Colo EV. The number of EVs was also nor-
malized for these experiments (see above). After a 7-
day incubation period, each experimental condition
was grown in soft agar to measure ability of anchorage
independent growth. A reduction in the number of col-
onies was viewed a shift towards a normal phenotype,
reflecting the inability of anchorage-independent
growth. The co-cultured cells were grown in soft agar
for 14 days. HCT116 cells co-cultured with 1459 EVs
displayed a significant decrease (p < 0.00001) in colony
formation in comparison to the control HCT116 cells
(Fig. 2a). A similar effect was seen from HCT116 cells
co-cultured with patient tissue derived vesicles. Co-
culture of HCT116 with 004CT Normal EVs and
HCT116 with Colo EVs both displayed significant de-
creases (p < 0.00001, p < 0.00001) in colony formation
(Fig. 2a). Our results suggest that EVs isolated from nor-
mal colon cells can mediate the reversal of malignant
phenotype in colon cancer. An additional co-culture was
set up with 1459 cells and EVs isolated from 1459 cells.
There was no significant difference between the number
of colonies formed by cells from 1459 + 1459 EV co-
cultures and 1459 control cells (p = 0.28).
In addition to assessing the inhibition of HCT116
phenotype by 1459 EV treatment via soft agar assay,
we performed transwell migration assay Our results
indicate that co-culture of HCT116 cells with non-
malignant 1459 EVs significantly inhibited cell migra-
tion (p < 0.0001) (Fig. 2b).
Mass Spectrometry analysis of proteins lysates obtained
from co-cultures
To further understand the mechanisms underlying the
phenotype switch occurring after EV co-culture, mass
spectrometry analysis was performed for protein identifi-
cation. After the 7-day co-culture period, cells were har-
vested and used for soft agar cloning. The remainder of
the cells were harvested and analyzed by mass spectros-
copy. Table 1 shows a partial list of the proteins identi-
fied in 1459 cells co-cultured with HCT116 EV, proteins
identified in 1459 cells co-cultured with 004CT Tumor
EV, and 1459 cells co-cultured with 1459 EVs. The rela-
tive expression of each protein, as compared to 1459
control, is indicated as log2 relative expression. Also in-
cluded in Table 1 are the log2 relative expressions of the
partial list of proteins identified in 1459 cells co-cultured
with HCT116 EV, as compared to HCT116 control.
Many of the isoforms in the 14-3-3 family of proteins
play key roles in promotion of a malignant phenotype
[17–19]. Our mass spectroscopy analysis revealed an in-
creased expression of 14-3-3 zeta/delta in co-cultures of
1459 cells with 004CT Tumor and HCT116 EVs, which
was confirmed with Western blot analysis (Fig. 3). Fur-
ther, a decrease in 14-3-3 zeta/delta was observed in
Fig. 1 Extracellular vesicle-mediated induction of soft-agar growth. EVs were isolated from malignant (HCT116) cells and from patient tumor tissue
(004CT Tumor). 1459 cells were co-cultured for 7 days with HCT116 EVs and 004CT Tumor EVs. In both experiments, cells were harvested and utilized
for soft agar assay. 1459 cells were also co-cultured with EVs isolated from 1459 cells. Soft agar cloning was performed for 2 weeks and cell colonies
were counted with 5 fields/dish using the 40× objective. There were 5 dishes/condition. To provide an estimation of colony size that was evaluated,
the area for the colonies counted in an average field was determined. The average area (μm2) determined were: 1459 CTRL, 1988; 1459 + 1459EV,
2603; 1459 + HCT EV, 1860; 1459 + 004CT Tumor EV, 3841. The data represents the mean +/− s.d. of 2 independent experiments performed in triplicate.
A paired t-test was performed to analyze the increase in soft agar colony formation of 1459 + HCT116 EVs when compared to untreated 1459 cells,
*p < 0.00001. Increase in colony formation of 1459 + 004CT Tumor EV compared to untreated 1459 cells, **p < 0.00001, was also assessed
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ports the notion that 14-3-3 is a key protein in impart-
ing the malignant phenotype of colon tumor cells.
Prohibitin and IGQAP1 were also identified by MS as
having similar expression patterns as the 14-3-3 pro-
teins. Increased expression of prohibitin and Raf-1 in
1459 co-cultures with malignant vesicles (HCT116 and
004CT Tumor) was validated with Western blotting
(Fig. 3). LC-MS/MS detected up-regulation of IGQAP1,
or Ras GTPase-activating-like protein, which we used as
basis to explore Raf-1 expression, due to recent research
implicating IGQAP1 as a key scaffold protein for the ac-
tivation of ERK1/2 [20]. Raf-1 is a major upstream regu-
lator of ERK1/2, two key proteins in the RAF-MEK-ERK
pathway controlling cell fate, including differentiation,
apoptosis and proliferation [21, 22]. Raf-1 function is
linked to increased levels of pRKIP [23], and Western
blotting revealed an increase in pRKIP expression in
1459 + HCT116 EV co-culture (Fig. 3). Prohibitin is seen
to be expressed at higher levels in many types of cancer
and is said to play a role in cell cycle regulation, apop-
tosis and cellular senescence [24, 25]. Of important note
is a decrease in prohibitin expression of 1459 cells co-
cultured with HCT116 EVs in comparison to control
HCT116 cells. Prohibitin was also not detected by MS in
the 1459 + 1459 EV co-culture. Again, similar to 14-3-3,
IGQAP1 was detected by MS to have a decreased expres-
sion in 1459 + 1459 EVs relative to 1459 control cells.
Signal Transducer and Activator of Transcription 1
(STAT1) is a member of the STAT family of transcrip-
tion factors. In the past, STAT1 was seen as a tumorsuppressor, however, recent research suggests that up-
regulation of STAT1 can promote immunosuppression
in the tumor microenvironment causing a more favor-
able environment for tumor growth [26, 27]. Mass spec-
trometry revealed an up regulation of STAT1 in 1459
co-cultured with HCT116 EVs, relative to both the 1459
and HCT116 control cells. Western blot analysis con-
firmed these results (Fig. 3).
Co-culture with malignant extracellular-vesicles increases
transcription of NF-κB
NF-κB signaling controls DNA transcriptions and cellu-
lar responses to stress, cytokines and both bacterial and
viral antigens. In particular, NF-κB has been implicated
in both anti-apoptotic and inflammatory processes in
the development and progression of CRC [28, 29]. After
a 7-day co-culture, HCT116, HCT116 +HCT EV, 1459
and 1459 + HCT EV cells were harvested and transfected
with a reporter plasmid to measure NF-κB activation, as
we have previously reported [16]. Forty eight hours after
transfection, cells were harvested, washed twice, lysed
and combined with a luciferase assay reporter. Relative
to 1459 control, 1459 cells co-cultured with malignant
EVs showed a significant increase (p = 0.00004) in NF-κB
transcription activity. A significant increase (p < 0.00001)
in NF-κB transcription was also seen in HCT116 cells
relative to 1459 cells (Fig. 4). No changes in NF-κB tran-
scription were seen between HCT116 cells and HCT116
co-cultured with HCT EVs (p = 0.21). We examined the
localization of p65 before and after HCT116 EV treat-
ment and determined that p65 remained in the cytosol
Fig. 2 Extracellular vesicle-mediated reduction of soft-agar growth. a EVs were isolated from non-malignant (1459) cells. HCT116 cells were
co-cultured for 7 days with 1459 EVs. EVs were also isolated from non-malignant patient tissue (004CT Normal and Colo) from 2 patients. HCT116
cells were co-cultured for 7 days with 004CT Normal EVs and Colo EVs, after which time soft agar was cloning was performed. An additional
co-culture was set up with HCT116 cells and HCT116 EVs. The data represents the mean +/− s.d. of 2 independent experiments performed in
triplicate. There were 5 dishes/condition. A paired t-test was performed to analyze the decrease in soft agar colony formation of HCT116 + 1459 EVs
when compared to untreated HCT116 cells, * p < 0.00001. Decrease in colony formation of HCT116 + 004CT Normal EV compared to untreated
HCT116 cells, **p < 0.00001, and HCT116 + Colo EV compared to untreated HCT116 cells, ***p < 0.00001, was also assessed. b Migration assay of HCT
cells with and without EV treatment. Migration was measured by counting the number of cells on the filter after 48 h. An increase in migration of
HCT116 cells relative to 1459 cells, *p < 0.0001, was analyzed using a paired t-test. Increased migration of 1459+ HCT EV compared to 1459 control cells,
**p < 0.0001, was also assessed
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nent of HCT116 EV cargo enhanced NF-κB transcrip-
tion. These findings support the role of NF-κB in the
promotion of CRC and suggest NF-κB as a target in EV-
mediated promotion of malignant phenotype.
Our results suggest the NF-κB activation in 1459 cells via
co-culture with HCT116 EVs promotes phenotype shifting.
To explore the role of NF-κB in phenotype shifting, we per-
formed NF-κB luciferase and migration assays in the pres-
ence of BAY117082 (BAY), a known inhibitor of NF-κBactivation in HCT116 cells [30]. 1459 NF-κB luciferase
transcription reporter activation and cell migration were
significantly reduced (p < 0.0001), respectively for both, in
cells treated with BAY and HCT116 EV (Fig. 4b, c).
siRNA repression of 14-3-3 zeta reduces extracellular-vesicle
mediated induction of malignant colon cancer phenotype
Repression of 14-3-3 zeta via siRNA knock-down in
HCT116 cells was used to observe the putative role of 14-
3-3 zeta in EV-mediated promotion of a malignant
Table 1 Comparison of some relative protein expression levels between 1459 co-cultured with malignant EVs a compared to 1459
control and HCT control
Accession
#
Protein name log2 Relative Expression
1459 v. 1459+ HCT EVs 1459 v. 1459 + 1459 EVs 1459+ 1459EV v. 1459+
004CT(T) EVs
HCT v. 1459 + HCT EVs
P08648 Integrin Alpha-5 1.593 −1.631 3.063 0.23
P05556 Integrin Beta-1 0.779 −1.429 4.118 −0.228
P35232 Prohibitin 1.503 3.652 −2.135
P27348 14-3-3 theta 1.208 −4.004 3.66 1.436
P63104 14-3-3 zeta/delta 0.276 −3.643 2.827 1.032
P46940 Ras GTPase-activating-like protein 2.792 −2.328 0.755 0.976
P42224 STAT1 2.459 2.38
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HCT116 cells were transfected with 14-3-3 zeta siRNA or
scramble siRNA for 48 h. After transfection, the cells were
grown for 7 days before harvesting. Media was collected
for EV isolation and cells were harvested for protein ly-
sates and soft agar assay. Western blot analysis confirmed
reduced expression of 14-3-3 in HCT116 cells transfected
with siRNA to 14-3-3 zeta, as compared to both HCT116
and HCT116 + scrambled siRNA controls (Fig. 5b). Non-Fig. 3 Extracellular vesicle mediated changes in cellular protein
expression. EVs were isolated from malignant HCT116 cells. EVs were
resuspended in PBS and co-cultured with non-malignant 1459 cells
and malignant HCT116 cells. Upon completion of the 7-day co-culture,
whole cell lysates were prepared for Western blot analysis, as reported.
Western blot analysis results show and increased expression of Raf-1,
pRKIP, STAT1, Prohibitin and 14-3-3 zeta/delta in 1459 + HCT116 EV
co-cultures, as compared to 1459 control. A slight decrease expression
of RKIP is also shown in this comparison. We examined these proteins
based on LC-MS data (Table 1)malignant 1459 cells were co-cultured with each of the
three types of vesicles for a period of 7 days. After 7 days,
cells were harvested for protein lysates and soft agar assay.
HCT116 cells with a reduced expression of 14-3-3 zeta
showed a significant decrease in colony formation, com-
pared to HCT116 cells transfected with control scramble
siRNA (p < 0.00001) (Fig. 5a). Additionally, the co-culture
of 1459 and vesicles isolated from HCT116 + 14-3-3
siRNA cells showed a significant decrease in colony for-
mation, compared to co-cultures with vesicles isolated
from HCT116 + scramble siRNA control (p = 0.0078)
(Fig. 5a). Western blot analysis confirmed the decrease in
endogenous 14-3-3 zeta levels (Fig. 5b). These results indi-
cate that 14-3-3 zeta may be responsible, in part, for con-
ferring the malignant phenotype via EVs in HCT116 cells.
We examined two other isoforms of 14-3-3 proteins,
sigma and epsilon, to determine if our affect on pheno-
type shifting was 14-3-3 zeta/delta-specific. Western blot
analysis indicated no change in the protein levels of 14-
3-3 sigma or epsilon after co-culture of 1459 cells with
HCT116 EV (Fig. 5c).
Lysates were prepared from HCT116 EVs after differ-
ential centrifugation to isolate the microvesicle, exosome
and total (microvesicle + exosome) fractions. Western
blot analysis indicated that 14-3-3 zeta/delta was present
in the total EV cargo content prior to co-culture experi-
ments (Fig. 5d).
Discussion
A more complete understanding of the tumor micro-
environment is critical in understanding underlying
mechanisms of metastatic disease. Abundant in this en-
vironment are membrane bound EVs, which are secreted
at increased rates in cells exhibiting a cancerous pheno-
type [10]. Through fusion with neighboring cells, EVs
act as mediators of horizontal protein and/or gene trans-
fer. Recent research has implicated this and other mech-
anisms resulting in the exchange of genetic material
between non-parent and donor cells, in tumor progres-
sion. Focus has been placed on cell-cell interactions
Fig. 4 Extracellular vesicle induced transcription of NF-κB. a EVs were
isolated from HCT116 cells. EVs were resuspended in PBS and co-
cultured with non-malignant 1459 cells and malignant HCT116 cells.
After 7 days of co-culture, cells were transfected with NF-κB reporter
plasmid to measure NF-κB transcriptional activation [16]. After 24 h, the
samples were harvested, washed twice, lysed and combined with a
luciferase assay reporter. The data is reported as the mean +/- s.d. of 2
independent experiments performed in triplicate. Relative to 1459,
HCT116 cells showed increased activity of NF-κB transcription,
*p < 0.00001. Increased relative activity of NF-κB transcription was also
seen in 1459 cells co-cultured with HCT116EVs, relative to 1459 control,
**p = 0.00004. b EVs were isolated from HCT116 cells and NF-κB
transcriptional reporterassay was performed as described in a in the
presence or absence of 3 μm BAY, a irreversible inhibitor of NF-κB [30].
Relative to 1459 control, 1459 cells in the presence of 3 μm BAY
showed decreased activity of NF-κB transcription, *p = 0.025. Increased
relative activity of NF-κB transcription was observed in 1459 cells
co-cultured with HCT116EVs, relative to 1459 control, **p < 0.0001. In
the presence of 3 μm BAY, 1459 + HCT116 EV cells showed decreased
activity of NF-κB transcription, as compared to those in the absence of
BAY, ***p < 0.0001. c Cell migration assay was performed using 1459
cells co-cultured with HCT116 EV in the presence or absence of 3 μm
BAY [30]. Relative to 1459 control, 1459 + BAY cells showed decreased
cellular migration, *p = 0.047, as assessed by paired t-test. An increase
in cellular migration was assessed in 1459+ HCT116 EV co-cultured
cells, relative to 1459 control, **p < 0.0001. Co-culture of 1459 cells with
EVs from HCT116 cells treated with 3 μM BAY showed decreased
cellular migration, ***p < 0.0001, compared to 1459 + HCT116 EV
co-cultured cells. The assay was performed twice in triplicate
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plasmids and viral particles [31]. There are, however,
other important factors secreted by cells. Ogata-Kawata,
et. al. recently identified seven micro-RNA found to be
overexpressed in serum samples from patients with
CRC, providing evidence that secreted factors might play
a role in the regulation of gene expression [32]. Simi-
larly, Kruger, et al, described differential expression of
miRNA in EVs isolated from two breast cancer cell lines
[33]. In another study, an induction of phenotypic
changes in prostate cancer cells through EV exposure
was detected. They also observed EV-mediated reversal
of chemosensitivity in otherwise resistant prostate can-
cer cell lines [34]. It is highly plausible that EVs can traf-
fic microRNA, which in turn mediates relevant changes
in protein expression. In our study, we focus on the role
of EVs in intracellular communication and identify their
capacity to induce phenotypic changes in colon cancer
cells. Observation of these changes supports the role of
EVs in the horizontal transfer of proteins and provides
targets for unique CRC therapies.
In this manuscript, we show that EVs can mediate the
transfer of both malignant and non-malignant cellular
phenotype in colon cells. EVs isolated from established
human colon cell lines and fresh patient tumor samples
were both shown to mediate changes in cellular pheno-
type, supporting the concept that these vesicles transfer
and/or induce biological components that enter the cells
Fig. 5 siRNA mediated Knock Down of 14-3-3 zeta/delta reduces soft agar colony formation. a HCT116 cells were transfected with siRNA to
14-3-3 zeta/delta, or equivalent amount of control siRNA solution. After 48 h incubation with siRNA to 14-3-3 zeta/delta, or equivalent amount of
control, HCT116 cells were harvested for soft agar cloning and saved for Western Blot analysis. EVs were harvested from the HCT116 cells transfected
with siRNA to 14-3-3 zeta/delta. EVs were resuspended in PBS and co-cultured with 1459 cells. After 7 days of co-culture, soft agar coloning was
performed. There were 5 dishes/condition. The data represents the mean +/− s.d. of 3 independent experiments performed in quadruplet. A paired
t-test was performed to analyze the decrease in soft agar colony formation of HCT116 transfected with 14-3-3 zeta/delta siRNA, compared to HCT116
transfected with scrambled siRNA as control, *p < 0.00001. Decrease in colony formation of 1459 + HCT116 14-3-3siRNA EV when compared to 1459 +
HCT116 scramble siRNA EV was assessed, ** p = 0.0039. b After co-culture, cells were harvested and a portion of the cells were prepared as whole cell
lysates for Western blot analysis. Western blot analysis confirmed the reduced expression of 14-3-3 zeta/delta in HCT116 + 14-3-3siRNA compared to
HCT116 and HCT116 + scramble siRNA controls. Reduced expression of 14-3-3 zeta/delta was also seen in the co-culture of 1459 + HCT116 14-3-3
siRNA EV as compared to 1459 + HCT116 EV and 1459 + HCT116 scramble siRNA EV controls. c Western blot analysis of 14-3-3 sigma and epsilon
protein levels of 1459 cells after co-culture with HCT116 EVs. d Western blot of 14-3-3 zeta/delta protein from vesicles isolated from 3 differential
centrifugation preparations. MV =microvesicle fraction; EX = exosome fraction; T =MV and EX fraction
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lated to malignancy. In vitro, we assessed malignant
phenotype through soft agar colony formation as quan-
tification of anchorage independent growth. Signifi-
cantly increased colony formation after co-culture of
normal colon cells with malignant-derived vesicles
(Fig. 1), and decreased colony formation and cell mi-
gration after co-culture of malignant colon cancer cells
with non-malignant-derived vesicles provides evidence
for phenotypic change (Fig. 2).
Along with identifying the ability of EVs to reverse and
promote malignancy in CRC, a major aim of this study
to was identify putative protein targets for noveltherapies. We used proteomic analysis to assess levels of
protein expression as a means of observing genetic
changes resulting from EV-mediated horizontal gene
transfer. Mass spectrometry analysis on samples of cells
before and after co-culture revealed significant alter-
ations in expression of key proteins, indicating that ei-
ther genetic material encoding proteins, or the proteins
themselves, are being released in EVs secreted by cells.
Observation of EV-mediated reversal of malignant
phenotype in colon cancer cells suggests EVs as a poten-
tial therapy for CRC. After evidence of phenotype
switching, we chose to further explore the protein
changes mediating the induction of malignancy, with the
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promoting an inherently non-malignant colon epithelial
cell to transform into one that exhibits a malignant
phenotype. Given that EVs have been found in serum, it
is possible that EVs released by localized colon tumor
cells can travel in the bloodstream and help to promote
metastasis [35, 36].
Our data suggests STAT1 is affected by the horizontal
transfer of genetic material, as mediated by EVs. STAT1
belongs to the family of STAT proteins that mediate the
transcription of various target genes by localizing to the
nucleus and binding to gene promoters, following activa-
tion by interferon-gamma [37]. We have shown that an-
other member of the STAT family, STAT3, has been
implicated in poor prognosis of CRC [38]. Conversely,
one of the largest arguments for STAT1 in cancer pro-
gression has been the reverse: a pro-apoptotic protein
acting as a tumor suppressor [39, 40]. The findings of
this study support another hypothesis that STAT1 be-
haves as an oncogenic protein. A small section of recent
research supports this argument. Hix et al identified a
relationship between increased expression of STAT1 and
breast cancer growth, attributed in part of the resulting
over expression of pro-inflammatory cytokines [41]. These
cytokines, including Interleukin-6 (IL-6), have been shown
to foster a microenvironment conducive to the progres-
sion of various types of cancer [42–44]. STAT1 up-
regulation was seen in the co-culture experiments,
supporting recent research suggesting an oncogenic role
of STAT1 in the tumor microenvironment. Future pro-
jects should aim to further understand the oncogenic role
of STAT1 and it’s validity as a drug target.
Prohibitin’s potential as an oncogenic protein is heavily
debated, given that it was first identified in tumor suppres-
sion through enhanced p53 transcription [25, 45, 46]. Sie-
vers et al recently identified a decrease in proliferation of
various cancer cell lines after silencing of prohibitin [25].
In another recent study, Panagopolous et al identified en-
hanced expression of prohibitin in EVs isolated from pa-
tient prostate tumor samples [34]. Our research further
supports the growing evidence implicating prohibitin in
tumor progression, given that our findings demonstrating
that 1459 cells acquire the ability to grow significantly in
soft agar when co-cultured with malignant EVs (Fig. 1).
These malignant EVs likely mediate a transfer of biomate-
rials causing an induction or direct transfer of prohibitin
as a mechanism of the non-malignant to malignant trans-
formation observed in our model.
The major pathway affected by changes in prohibitin
levels is the RAF-MEK-ERK pathway, which serves as a
major mediator of a variety of signaling pathways con-
trolling the survival of cells, as well as differentiation
and cell-cycle regulation [47]. IQGAP1, or Ras GTPase-
activating-like protein, has also been identified as animportant regulator of the RAF-MEK-ERK pathway, spe-
cifically with increased expression of IQGAP1 leading to
increased phosphorylation of ERK1/2 [21, 47, 48]. Ana-
lysis of LC-MS/MS data indicated an increased expression
of this protein in co-cultures of 1459 with malignant EVs.
Based upon our proteomics findings, we further explored
the expression of Raf-1 and its regulatory proteins. Raf-1 is
an upstream regulator of the RAF-MEK-ERK pathway, re-
cruited by Ras in response to growth factor and/or cytokine
signaling. Activation of Raf-1, through phosphorylation, in-
turn leads to a phosphorylation cascade of MAPK kinases
that compose the RAF-MEK-ERK dependent regulation of
cell processes [49, 50].
RKIP is known to interfere with function of Raf-1 by
preventing its ability to then phosphorylate MEK to con-
tinue the signaling cascade. More specifically, Raf-1 is
bound by RKIP at the phosphorylated N-terminal, which
blocks the binding of MEK [51]. Binding between RKIP
and MEK has also been seen, again, blocking the signal
cascade [52]. Decreased expression of RKIP by micro-
RNA224 has previously been implicated in metastasis of
breast cancer [53]. MicroRNA, however, is just one
mechanism responsible for reduced RKIP expression in
cells. Phosphorylation of RKIP by protein kinase C
(PKC) at the Ser153 residue leads to inactivation, caus-
ing the release of Raf-1 and subsequent reestablishment
of RAF-MEK-ERK mediated proliferation [24]. Studies
of CRC patient tumor samples by Minoo,et al show an
association between poor prognosis and reduced or lost
expression of RKIP [54]. Cross-Knorr et al shows a similar
association, recognizing an increased expression of pRKIP
in CRC patients with poor prognosis [38]. Western blot
analysis of our co-culture samples showed an increased
expression of Raf-1 and pRKIP in 1459 +HCT EV com-
pared to 1459 controls (Fig. 3), supporting these findings
and further implicating the RAF-MEK-ERK pathway in
the induction of malignancy by EVs.
LC-MS/MS data indicated IQGAP1 was expressed at a
significantly lower level after 1459 co-culture with its own
non-malignant vesicles, and prohibitin was undetectable
by mass spectrometry in the same condition. Given the re-
duction in expression, it is plausible that the 1459 EVs
carry miRNA acting to down regulate key proteins in
RAF-MEK-ERK mediated signaling. This indicates the po-
tential that EVs secreted from non-malignant and malig-
nant cells affect the same pathways in reciprocal fashion.
Vesicles isolated from non-malignant colon cells and ma-
lignant colon cells should be further assessed for genetic
profiles, including miRNA content, for a better under-
standing of the mechanism behind EV induced mediation
of key protein levels.
In addition to inhibiting the RAF-MEK-ERK cascade,
RKIP is also known to have an inhibitory effect on the
NF-κB pathway through upstream interactions with its
Fig. 6 Schematic representing our model indicating the transfer of
14-3-3 zeta/delta (circles) by HCT116 EVs with the activation of NF-κB
with downstream signaling events regulated by both 14-3-3 zeta/delta
and NF-κB leading to the malignant phenotype that is inhibited by
non-malignant EVs
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key roles in both anti-apoptotic processes of the cell, as
well as promotion of inflammation. Enhanced expression
of NF-κB transcription factors have been linked to a var-
iety of human carcinomas, including CRC tumors [56, 57].
NF-κB is activated through the degradation of its inhibi-
tory proteins, leading to release of the NF-kB dimer and
it’s translocation to the nucleus [58]. NF-κB then targets
specific DNA sequences to facilitate gene expression, spe-
cifically of genes critical in cellular death. Normally, tumor
necrosis factor (TNF) would initiate a signaling cascade
through the binding of caspase-8 and FADD, leading to
apoptosis in the cell [59]. However, increased levels of
TRAF1 and TRAF2, as a result of NF-κB expression, were
enough to block this caspase-8 activation and inhibit cell
death [60].
Additionally, a significant increase in NF-κB expres-
sion is seen in both patients with inflammatory bowel
disease, as well as Helicobacter pylori induced gastritis
[61]. This increase in NF-κB is coupled with increased
levels of pro-inflammatory cytokines including e-selectin
and Interleukin-8 [62]. An inflammatory environment
has been implicated in tumor progression. In our experi-
ment, luciferase reporter assay of 1459 + HCT116 EV
co-culture revealed increased transcriptional activity of
NF-κB, relative to 1459 control (Fig. 4a). HCT116 EV-
mediated 1459 NF-κB activation and cell migration were
abrogated in the presence of the irreversible NF-κB in-
hibitor BAY (Fig. 4b,c). Thus, our findings suggest that
malignant EVs induce expression of NF-κB as a means
of suppressing apoptosis in HCT116 cells and promoting
an inflammatory microenvironment that aids in the
transformation to a malignant phenotype.
We observe enhanced levels of 14-3-3 zeta/delta in 1459
cells following co-culture with HCT116 and patient de-
rived malignant EVs through both proteomic and Western
blot analysis. (Table 1, Fig. 3a). The 14-3-3 family of seven
distinct proteins serves a diverse role in cellular function
through binding with kinases, phosphatases and trans-
membrane receptors to regulate intracellular signaling,
cell cycle control, apoptosis and proliferation [18]. Of the
14-3-3 proteins, 14-3-3 sigma has been implicated in both
tumor suppression through regulation by p53, and tumor
progression. While initial findings supported 14-3-3
sigma-related cell-cycle arrest, recent publications provide
contradictory evidence which suggests increased expres-
sion of 14-3-3 sigma in cancer cells [63]. Knock-down of
14-3-3 sigma decreased resistance to cisplatin in CRC,
suggesting pro-apoptotic function of 14-3-3 sigma [64].
Similarly, other members of the 14-3-3 family have been
identified as up-regulated in multiple cancers [19, 65].
14-3-3 zeta/delta has been specifically been linked to
regulation of Raf function through accompaniment to
the cellular membrane [66].Further investigation into the role of 14-3-3 zeta/delta
in EV-mediated transformation of colon cells was com-
pleted through a reduction of protein expression using
siRNA. 1459 cells co-cultured with EVs harvested from
HCT + 14-3-3 siRNA cells showed reduced soft agar
growth, relative to co-cultures with control HCT +
scramble siRNA EVs (Fig. 5a). This finding, coupled with
decreased soft agar colony formation in HCT + 14-3-3
siRNA cells compared to HCT + scramble siRNA con-
trols (Fig. 5a), supports the hypothesis that 14-3-3 zeta/
delta is responsible, in part, for EV-mediated transform-
ation. Cells expressing lower levels of 14-3-3 zeta/delta
see a reduced capacity for 14-3-3 secretion in EVs, and
are therefore limited in their ability to induce phenotypic
changes in neighboring cells. Our results do not indicate
any alterations in 14-3-3 sigma or epsilon protein levels
after co-culture with HCT116 EVs (Fig. 5c). This indi-
cates, again, that 14-3-3 zeta/delta is likely responsible
for the phenotypic changes we observe, which is corrob-
orated by the presence of 14-3-3 zeta/delta in the cargo
of HCT116 EV (Fig. 5d).
Along with promoting tumorigenesis through regula-
tion of the RAF-MEK-ERK pathway, 14-3-3 proteins
have also been implicated in the binding of pro-
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[20]. The BCL-2 family of proteins are key regulators of
apoptosis through control of mitochondrial outer mem-
brane permeabilization (MOMP). In the mitochondria,
BAD mediates the formation of a heterodimer between
anti-apoptotic proteins BCL-2 and BCL-XL, thus pre-
venting their inhibition of BAX (BCL-2-associated X
protein) [67]. BAX is a key protein required to form
mitochondrial pores allowing mitochondrial proteins, in-
cluding cytochrome c, to activate caspases in the cytosol,
resulting in apoptosis [68, 69]. We observe increased ex-
pression of 14-3-3 in cells expressing malignant pheno-
type (Fig. 3), providing further evidence that 14-3-3 is
crucial in cell survival through binding of BAD to pre-
vent its relocation to the mitochondria. Given their dual
role in the survival and proliferation of cells, 14-3-3 pro-
teins may serve as a key targets in therapies for CRC.
Collectively, our results indicate that HCT116 EVs carry
14-3-3 zeta/delta as part of their cargo that is transferred
to recipient cells after co-culture (Fig. 6). This also results
in the activation of NF-κB (Fig. 6). Consequently, there is
a promotion of a series of events leading to HCT116 can-
cer cell survival, which can be abrogated, in part, by co-
culture with non-malignant EVs (Fig. 6).
Conclusion
In summary, this study identifies EVs as an important me-
diator of horizontal transfer of genetic material in the pro-
motion of a malignant phenotype with an increased
expression of key RAF-MEK-ERK pathway mediating
proteins including 14-3-3 zeta/delta, Raf-1, pRKIP and
NF-κB. These proteins may serve as key targets for novel
therapies in patients with CRC tumors. Additionally, EV-
mediated reversal of malignant phenotype was observed
in this study, suggesting the use of EVs as tumor bio-
markers or as a therapeutic agent. Analysis of the contents
of both malignant and non-malignant CRC EVs derived
from patient samples, in the future, would provide add-
itional data for the assessment of EVs as therapeutic agent
or for biomarkers (i.e., 14-3-3 and prohibitin) for potential
therapeutic targets and drug development for CRC.
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